Inactive Instrument

Loon Energy Corporation Stock Toronto S.E.

Equities

LNE.H

CA5435123057

Biotechnology & Medical Research

Sales 2023 170K 125K Sales 2024 123K 90.17K Capitalization 490K 360K
Net income 2023 -3M -2.2M Net income 2024 -1M -733K EV / Sales 2023 23.4 x
Net Debt 2023 61.19K 44.87K Net Debt 2024 96.94K 71.09K EV / Sales 2024 4.78 x
P/E ratio 2023
-1.07 x
P/E ratio 2024
-0.36 x
Employees -
Yield 2023 *
-
Yield 2024
-
Free-Float 95.77%
More Fundamentals * Assessed data
Dynamic Chart
Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in funding CI
Optimind Pharma Corp. Reports Earnings Results for the Full Year Ended February 29, 2024 CI
Optimind Pharma Reaches Agreement On Debenture Conversion MT
Optimind Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 CI
Optimind Pharma Corp. Announces Executive Changes CI
Optimind Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023 CI
Optimind Pharma Corp. Reports Earnings Results for the First Quarter Ended May 31, 2023 CI
Optimind Pharma Corp. Auditor Raises 'Going Concern' Doubt CI
Optimind Pharma Corp. Reports Earnings Results for the Full Year Ended February 28, 2023 CI
Optimind Pharma Corp. acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million. CI
Optimind Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Optimind Pharma Corp. Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma Corporation CI
Optimind Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Optimind Pharma Inc. completed the acquisition of Loon Energy Corporation (TSXV:LNE.H) in a reverse merger transaction. CI
Optimind Pharma Corp. announced that it has received CAD 0.507 million in funding CI
More news
Optimind Pharma Corp. is a Canada-based emerging provider of psychedelic therapies for the masses. The Company helps people suffering from post-traumatic stress disorder (PTSD), anxiety, depression and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. The Company also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings. Its treatment programs are designed based on scientific research and specific modalities used in many different therapeutic practices. Each treatment program combines the use of psychedelic medicine with therapeutic processing and integration. It has two different types of treatments. Monotherapy and assisted therapy, all based on a Ketamine capsule. The effects are felt about 30 minutes after, and within two hours of taking the medicine, cognition is resorted to normal.
More about the company